Clinical Trial Update: Efficacy of Ultrasound Contrast Agent to Assess Renal Masses [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy of an ultrasound contrast agent for assessing renal masses, including renal cell carcinoma, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Ultrasound Contrast Agent

Snippet

Sponsor: University Health Network, Toronto | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED